The DUS1L Knockout NCI-H1975 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 non-small cell lung adenocarcinoma line, engineered to disrupt the human DUS1L gene. This polyclonal pool contains a heterogeneous mix of edited alleles, providing a robust loss-of-function model for interrogating tRNA dihydrouridylation without the selective pressure or clonal artifacts inherent to single-cell-derived lines. The product is supplied as a live cell population suitable for immediate expansion and downstream functional analyses, enabling flexible experimental designs in epitranscriptomic and cancer biology workflows.
The host NCI-H1975 cell line is a broadly used model of lung adenocarcinoma, originally established from a female patient and characterized by endogenous EGFR L858R and T790M activating mutations. These molecular features confer sensitivity to first- and second-generation EGFR tyrosine kinase inhibitors and recapitulate key aspects of oncogenic signaling in non-small cell lung cancer. The cells exhibit adherent epithelial morphology and are well-suited for in vitro assays of proliferation, drug response, and signal transduction, making them a relevant platform for studying genetic perturbations in the context of EGFR-driven lung cancer.
DUS1L encodes a tRNA-dihydrouridine synthase that catalyzes the NADPH-dependent reduction of uridine to dihydrouridine at multiple positions in the D-loop of cognate tRNAs, thereby stabilizing tRNA tertiary structure and promoting translational fidelity. Its activity is transcriptionally regulated by oncogenic factors such as MYC and likely E2F1, placing DUS1L downstream of growth-control networks. The enzyme interacts dynamically with tRNA substrates and collaborates with other modification enzymes; its dihydrouridine modification influences the decoding efficiency of specific codons and modulates the translation of growth-related mRNAs. Disruption of DUS1L thus impairs tRNA maturation, potentially triggering translational reprogramming and cellular stress responses that converge on translation elongation factors.
In the NCI-H1975 background, ablation of DUS1L creates a unique opportunity to dissect how tRNA modification status intersects with EGFR-driven oncogenic programs. Given the heightened translational demand in cancer cells, loss of dihydrouridine-dependent tRNA stabilization may selectively compromise the synthesis of proteins critical for tumor maintenance, revealing synthetic vulnerabilities linked to codon usage. This polyclonal knockout model therefore enables investigation of the epitranscriptomic layer of gene regulation within a clinically relevant NSCLC setting, facilitating the study of how changes in tRNA biology influence cancer cell fitness and therapeutic susceptibility.
Researchers can employ this knockout population to address mechanistic questions across a spectrum of experimental approaches. Representative assays include RT-qPCR to verify transcript-level disruption, western blotting or LC-MS-based detection of dihydrouridine to assess tRNA hypomodification, and proliferation or colony formation assays to quantify growth phenotypes. Polysome profiling can reveal alterations in global or transcript-specific translation, while complementary biochemical approaches allow probing of interactions with other tRNA modification enzymes. These readouts support applications ranging from basic epitranscriptomic discovery to translational studies of tRNA regulation in lung adenocarcinoma. For additional details or customized support, please contact Ascent Research.
